ACACA and Alzheimer disease: Currais et al. (2019) reported that AD drug candidate compounds increase acetyl-CoA in aging SAMP8 mice by inhibiting ACC1, an enzyme involved in acetyl-CoA catabolism, and have neuroprotective effects through histone acetylation, enhancing memory and maintaining mitochondrial homeostasis.